Tissue & Biologics is a rapidly growing sector in the thriving regenerative medicine industry. Historically, Minnesota has been a pioneer in tissue-based products and biologics. In fact, the first pre-market approvals issued in the state were to Coloplast and Synovis Surgical Innovations for vocal cord augmentation and vascular reconstruction respectively.
There has been continued growth in the sector since the 1970s, which has led to a burgeoning cluster of biologics companies developing novel therapies using cell or tissue-based approaches to repair or replace organs and tissues.
Using core community competencies in cardiovascular diseases, unique tissue and biomaterial processing technologies and tissue transplantation capabilities, the Tissue & Biologics sector in Minnesota is developing unique products that are advancing the field of regenerative medicine.
The companies in this industry are succeeding by taking advantage of the strong ecosystem created by the medical device companies, supportive infrastructure at the University of Minnesota and Mayo Clinic and a highly educated workforce with a history of innovation. The primarily small companies and startups in this industry have been able to garner support from the investment community. In 2014, life science investment in the region set a five-year high; investments in both pharma and biotech companies increased ten-fold over 2013 levels. Read more by clicking on one of the links below.
Thank you to Gold Sponsor Dohmen Life Science Services for its support of the Tissue & Biologics Sector Landscape.